MoonLake Reports VELA Phase 3 HS Results with Sonelokimab
MoonLake Immunotherapeutics reported week 16 readouts from its two pivotal Phase 3 trials in hidradenitis suppurativa. In VELA-1, sonelokimab...
eClinical Tech News
Onconetix’s New Focus: Secures Financing, Ends Ocuvex Deal
Onconetix has closed a $12.9 million private placement comprising Series D convertible preferred stock and warrants, using the raise...
FDA Approves Evkeeza for Rare High Cholesterol in Children
FDA has expanded Evkeeza (evinacumab-dgnb) to children aged 1 to under 5 with homozygous familial hypercholesterolemia, completing a stepwise...
Strategic Partnership to Accelerate Immunotherapy Innovation
OSE Immunotherapeutics has entered a strategic partnership with Inserm Transfert and Nantes University to source, mature, and industrialize early-stage...
BioXcel Therapeutics Announces Positive Topline Results from Phase 3 SERENITY Trial of BXCL501
BioXcel Therapeutics reported that its pivotal Phase 3 SERENITY at-home study met its primary endpoint, demonstrating that a 120...
Quell Therapeutics Forms World-Class Scientific Advisory Board
Quell Therapeutics has convened a new scientific advisory board to steer its engineered T-regulatory cell therapy portfolio, adding heavyweight...
Mesoblast Triumphs With First FDA Approval, Ryoncil Launch
Mesoblast has closed its fiscal year with the first FDA-approved mesenchymal stromal cell therapy on the U.S. market and...
Codexis Will Participate in Cantor Global Healthcare Conf
Codexis will present at the Cantor Global Healthcare Conference in New York on September 4, 2025, with a webcast...
VTV Therapeutics Secures Mammoth $80M Private Placement
vTv Therapeutics has secured an $80 million PIPE to fund the ongoing CATT1 phase 3 trial and continued development...
EU Panel Backs Dupixent for Chronic Spontaneous Urticaria
Europe’s drug regulator has issued a positive opinion for dupilumab in chronic spontaneous urticaria, recommending approval for adults and...